FY2027 EPS Estimates for Envista Cut by Leerink Partnrs

Envista Holdings Co. (NYSE:NVST - Free Report) - Analysts at Leerink Partnrs decreased their FY2027 EPS estimates for Envista in a research note issued to investors on Wednesday, April 9th. Leerink Partnrs analyst M. Cherny now anticipates that the company will earn $1.28 per share for the year, down from their previous forecast of $1.45. The consensus estimate for Envista's current full-year earnings is $1.00 per share.

A number of other equities analysts have also recently weighed in on the stock. Wells Fargo & Company set a $19.00 price objective on shares of Envista in a research report on Saturday, March 8th. Piper Sandler raised their price objective on Envista from $17.00 to $18.00 and gave the stock a "neutral" rating in a research note on Monday, February 3rd. Needham & Company LLC reiterated a "hold" rating on shares of Envista in a research note on Thursday, March 6th. Jefferies Financial Group increased their price objective on shares of Envista from $20.00 to $22.00 and gave the stock a "hold" rating in a research note on Thursday, January 23rd. Finally, JPMorgan Chase & Co. decreased their target price on Envista from $20.00 to $19.00 and set a "neutral" rating for the company in a research note on Thursday, March 6th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $19.96.

Envista Stock Up 0.9 %

Shares of NYSE NVST traded up $0.13 during trading on Monday, reaching $15.15. 984,026 shares of the stock were exchanged, compared to its average volume of 2,477,534. The business's 50-day moving average price is $18.05 and its 200 day moving average price is $19.27. The company has a market capitalization of $2.61 billion, a price-to-earnings ratio of -2.34, a price-to-earnings-growth ratio of 1.27 and a beta of 1.12. Envista has a twelve month low of $14.22 and a twelve month high of $23.00. The company has a quick ratio of 1.76, a current ratio of 2.04 and a debt-to-equity ratio of 0.44.

Remove Ads

Envista (NYSE:NVST - Get Free Report) last posted its earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%.

Hedge Funds Weigh In On Envista

Several hedge funds have recently made changes to their positions in the business. Thurston Springer Miller Herd & Titak Inc. acquired a new position in Envista in the fourth quarter worth approximately $53,000. Lecap Asset Management Ltd. acquired a new position in shares of Envista in the 4th quarter worth $281,000. Geode Capital Management LLC raised its position in shares of Envista by 2.5% during the third quarter. Geode Capital Management LLC now owns 2,895,653 shares of the company's stock worth $57,233,000 after purchasing an additional 71,435 shares during the period. Hantz Financial Services Inc. lifted its holdings in shares of Envista by 146.6% during the fourth quarter. Hantz Financial Services Inc. now owns 110,489 shares of the company's stock valued at $2,131,000 after purchasing an additional 65,679 shares during the last quarter. Finally, Norges Bank acquired a new position in shares of Envista in the 4th quarter valued at $38,052,000.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.